Ahmed, H. (2004). Chapter 1: Extraction of protein. Ahmed, H. (Ed.). Principles and reactions of protein extraction, purification, and characterization. CRC Press, London.

Blanco, E., Shen, H., & Ferrari, M. (2014). Pharmacokinetics and biodistribution of nanoparticles in cancer drug delivery: Mechanisms and implications. Current Drug Metabolism, 15(2), 137–150.

Christmann, M., Verbeek, B., Roos, W. P., & Kaina, B. (2011). O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochimica et Biophysica Acta – Reviews on Cancer, 1816(2), 179–190.

Eisenberg-Lerner, A., Bialik, S., Simon, H. U., & Kimchi, A. (2009). Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death and Differentiation, 16, 966–975.

Galluzzi, L., Lopez-Soto, A., Kumar, S., & Kroemer, G. (2016). Caspases connect cell-death signaling to organismal homeostasis. Immunity, 44(2), 221–231.

Hijioka, S., Sakuma, K., Aoki, M., Mizuno, N., Kuwahara, T., Okuno, N., Hara, K. & Yatabe, Y. (2019). Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemotherapy and Pharmacology, 83(1), 43–52.

Jensen, C., & Teng, Y. (2013). In vitro vs. in vivo models for studying cancer. Biotechnology Journal, 8(10), 1099–1106.

Jiang, G., Jiang, A. J., Xin, Y., Li, L. T., Cheng, Q., & Zheng, G. N. (2014). Progression of O6-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. Molecular Biology Reports, 41(10), 6659–6665.

Kaina, B., Margison, G. P., & Christmann, M. (2010). Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cellular and Molecular Life Sciences, 67(21), 3663–3681.

Kotsarenko, K., Lylo, V., Ruban, T., Macewicz, L., & Lukash, L. (2018). Effects of some growth factors and cytokines on the expression of the repair enzyme MGMT and Protein MARP in human cells in vitro: Effect of some growth factors and cytokines. Biochemical Genetics. 56(5), 459–477.

Latypov, V. F., Tubbs, J. L., Watson, A. J., Marriot, A. S., McGown, G., Thorncroft M., Wilkinson, O. J., Senthong, P., Butt, A., Arvai, A. S., Millington, C. L., Povey, A. C., Williams, D. M., Santibunez-Koreff, M. F., Tainer, J. R., & Margison, G. P. (2012). Atl1 regulates choice between global genome and transcription-coupled repair of O(6)-alkylguanines. Molecular Cell, 47(1), 50-60.

Li, X., Yang, C., Luo, N., Yang, Y., Guo, Y., Chen, P., & Cun, B. (2022). Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment. Cancer Biomarkers, 34(2), 275–284.

Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today: Technologies, 1(4), 337–341.

Maki, Y., Murakami, J., Asaumi, J. I., Tsujigiwa, H., Nagatsuka, H., Kokeguchi, S., Fukui, K., Kawai, N., Yanagi, Y., Kuroda, M., & Tanaka, N. (2005). Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum (II) in oral cancer cell lines. Oral Oncology, 41(10), 984–993.

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791.

Nyskohus, L. S., Watson, A. J., Margison, G. P., Le Leu, R. K., Kim, S. W., Lockett, T. J., Head, R. J., Young, G. P., & Hu, Y. (2013). Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 758, 80–86.

Ortiz, R., Perazzoli, G., Cabeza, L., Jiménez-Luna, C., Luque, R., Prados, J., & Melguizo, C. (2021). Temozolomide: An updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Current Neuropharmacology, 19(4), 513–537.

Pan, Y., Liu, G., Zhou, F., Su, B., & Li, Y. (2018). DNA methylation profiles in cancer diagnosis and therapeutics. Clinical and Experimental Medicine, 18(1), 1–14.

Pedretti, A., Mazzolari, A., Gervasoni, S., Fumagalli, L., & Vistoli, G. (2021). The vega suite of programs: A versatile platform for cheminformatics and drug design projects. Bioinformatics, 37(8), 1174–1175.

Pegg, A. E. (2011). Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chemical Research in Toxicology, 24(5), 618–639.

Quail, D. F., & Joyce, J. A. (2017). The tumor microenvironment and its contribution to tumor evolution toward metastasis. Cancer Metastasis Reviews, 36(3), 529–544.

Ranson, M. (2006). Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clinical Cancer Research, 12(5), 1577–1584.

Sahoo, G., Samal, D., Khandayataray, P., & Murthy, K. (2023). A review on caspases: Key regulators of biological activities and apoptosis. Molecular Neurobiology, 60, 5805–5837.

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Mechanisms of resistance to checkpoint inhibition in cancer immunotherapy. Nature Reviews Clinical Oncology, 14(4), 193–203.

Su, M., Mei, Y., & Sinha, S. (2013). Role of the crosstalk between autophagy and apoptosis in cancer. Journal of Oncology, 2013, 102735.

Tomaszowski, K. H., Hellmann, N., Ponath, V., Takatsu, H., Shin, H. W., & Kaina, B. (2017). Uptake of glucose-conjugated MGMT inhibitors in cancer cells: Role of flippases and type IV P-type ATPases. Scientific Reports, 7, 13925.

Tomaszowski, K. H., Schirrmacher, R., & Kaina, B. (2015). Multidrug efflux pumps attenuate the effect of MGMT inhibitors. Molecular Pharmaceutics, 12(11), 3924–3934.

Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008). O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. British Medical Bulletin, 85(1), 17–33.

Yu, W., Zhang, L., Wei, Q., & Shao, A. (2020). O6-Methylguanine-DNA methyltransferase (MGMT): Challenges and new opportunities in glioma chemotherapy. Frontiers in Oncology, 9, 1544.

Zhuvaka, K. S., Piven, O. O., Macewich, L. L., Ruban, T. P., Volynets, G. P., Yarmoluk, S. M., Dobrzyn, P., & Lukash, L. L. (2024). Novel MGMT inhibitors increase the sensitivity of glioma MGMT-positive cells to treatment with alkylating agents in vitro. Biopolymers and Cell, 40(1), 47–57.

Zhuvaka, K. S., Volynets, G. P., Ruban, T. P., Nidoeva, Z. M., Iatsyshyna, A. P., Macewizc, L. L., Bdzhola, V. G., Yarmoluk, S. M., & Lukash, L. L. (2023). Activity of nonnucleoside inhibitors of O6-methylguanine-DNA methyltransferase repair enzyme in human cells in vitro. Cytology and Genetics, 57(6), 48–59.